NURIX THERAPEUTICS IN

Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

25 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

20 Nov 2024 15:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting

05 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

31 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit

21 Oct 2024 15:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia

19 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur

16 Oct 2024 15:35:41 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

11 Oct 2024 15:00:28 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology

09 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations at Discovery on Target Conference

30 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit

06 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

29 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

11 Jul 2024 15:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in the UBS Virtual Targeted Protein Degradation (TPD) Day

08 Jul 2024 06:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)

16 Jun 2024 04:30:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)

10 Jun 2024 06:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

29 May 2024 06:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer

28 May 2024 06:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Board Chair Transition

20 May 2024 15:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)

14 May 2024 09:00:00 By Nasdaq GlobeNewswire